131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma - Phase I and II study

Acta Oncologica

Volumn 38, Issue 3, 1999, Pages 351-359

  Riva, Pietro ^c   Franceschi, Giancarlo ^a   Frattarelli, Massimo ^a   Riva, Nada ^a   Guiducci, Graziano ^a   Cremonini, Anna Maria ^a   Giuliani, Graziano ^a   Casi, Michela ^a   Gentile, Rossella ^a   Jekunen, Annti A ^b   Kairemo, Kalevi J A ^b  

^a Dept of Neurosurg 'MBufalini' H ^*

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c BUFALINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; IODINE 131; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN EDEMA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; RADIOISOTOPE THERAPY; GLIOMA; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; QUALITY OF LIFE; RADIATION RESPONSE; SURVIVAL RATE; TISSUE DISTRIBUTION;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 0032588925     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699431438     Document Type: Article

References (22)

1. 1. Loeffler JS, Shrieve DC, Coleman CN. Chemoradiation and adjuvant chemotherapy: why does so much therapy yield so little improvement in survival? Int J Radiat Oncol Biol Phyis 1995; 33: 531-3.
2. 2. Jeremic B, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y. Influence of the extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol 1994; 21: 177-85.
3. 3. Jubelirer SJ. A review of the treatment and survival rates of 138 patients with glioblastoma multiforme. W V Med J 1996; 92: 186-90.
4. 90Yttrium labeled monoclonal antibody MUC 2-63. In: Epenetos A, ed. Monoclonal antibodies: applications in clinical oncology. London, New York: Chapman and Hall Medica, 1992: 17-25.
5. 5. Papanastassiou V, Pizer BL, Coakham HB, et al. Treatment of recurrent and cystic malignant glioma by a single intracavitary injection of I-131 monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993; 67: 144-51.
6. 131I-labelled anti-tenascin monoclonal antibody. Int J Cancer 1992; 51: 7-13.
7. 7. Leprini A, Querze G, Zardi L. Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect Dev Neurobiol 1994; 2: 117-23.
8. 131I-labeled antitenascin monoclonal antibody 81C6. Cancer Res 1988; 48: 2904-10.
9. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989; 49: 2807-13.
10. 10. Arista A, Sturiale C, Riva P, et al. Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas. Acta Neurochir 1995; 135: 159-62.
11. 11. P. Riva, A. Arista, C. Sturiale, et al. Intralesional therapy of glioma In: New antibody technology and the emergence of useful cancer therapy. Begent R, Hamblin A, eds. London: The Royal Society of Medicine Press, 1995: 23-6.
12. 12. Kaplan EI, Maier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
13. 13. Riva P, Arista A, Tison V, et al. Intralesional radioimmunotherapy of malignant glioma: an effective treatment in recurrent tumors. Cancer 1994; 73 (Suppl): 1076-82.
14. 14. Muto MG, Finkler NJ, Kassis AI, Lepisto EM, Knapp RC. Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125. Gynecol Oncol 1990; 38: 244-8.
15. 15. Sturiale C, Arista A, Lazzari S, et al. Intralesional radioimmunotherapy of malignant gliomas: clinical experiences with recurrent and primary tumours. Tumor Targeting 1995; 1: 163-76.
16. 16. P. Riva, A. Arista, C. Sturiale, et al. Radioimmunotherapy of CNS malignant gliomas by direct intralesional injection of specific I-131 radiolabeled monoclonal antibodies. In: Cancer therapy with radiolabeled antibodies. Goldenberg DM, ed. Boca Raton, Ann Arbor, London, Tokyo: CRC Press, 1995: 203-16.
17. 17. Riva P, Arista A, Sturiale C, et al. Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies. Cell Biophysics 1994; 24/25: 37-43.
18. 18. Baum RP, Niesen A, Hertel A, et al. Activating anti-idiothypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;73 (Suppl): 1121-5.
19. 19. Brady LW, Miyamoto C, Woo DV, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992; 22: 225-30.
20. 20. Hopkins K, Chandler C, Bullimore J, et al. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 1995; 34: 121-31.
21. 131I. Comparison of the results obtained in recurrent and newly diagnosed tumours. Cancer Res 1995; 55: 5952s-6s.
22. 22. Riva PG, Franceschi G, Arista A, et al. Local application of radiolabeled MAbs for the treatment of high grade malignant gliomas: a six year clinical experience. Cancer 1997; 80 (Suppl): 2733-42.